A Phase 1 interventional study of SGC001 and Placebo in Anterior Myocardial Infarction, sponsored by Beijing Sungen Biomedical Technology Co., Ltd. Completed at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Beijing Sungen Biomedical Technology Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction. SGC001 might reduce the infarct size and inhibited inflammation, thereby preventing the incidence of major adverse cardiovascular events(MACE) events. Participants will either get SGC001 (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting SGC001 or placebo is the same. The participant was administered intravenously once. SGC001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe.
36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.
This study's enrollment of 38 is below the median of 110 across 28 interventional studies indexed under Anterior Wall Myocardial Infarction.
Browse Anterior Wall Myocardial Infarction studies →Beijing Sungen Biomedical Technology Co., Ltd is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals with the following medical histories:
Individuals with the following medical histories:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled anterior STEMI patients will receive standard clinical treatment and a single dose of SGC001 on Day 1 (D1) according to their randomized dosing group. The study drug should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection will be administered over 10 minutes.
Drug: SGC001
Enrolled anterior STEMI patients will receive standard clinical treatment and a single dose of placebo on Day 1 (D1) according to their randomized dosing group. The study drug should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection will be administered over 10 minutes.
Drug: Placebo
The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
Adverse events (AE), Serious adverse events (SAE)
Adverse events (AE), Serious adverse events (SAE)
Time frame: From randomisation to end-of-study (up to 30 days)
Recommended Phase 2 dose (RP2D)
Determination of the Recommended Phase II Dose
Time frame: From randomisation to end-of-study (up to 30 days)
Peak Concentration (Cmax)
Peak Concentration (Cmax)
Time frame: From randomisation to end-of-study (up to 30 days)
Time to Maximum Concentration (Tmax)
Time to Maximum Concentration (Tmax)
Time frame: From randomisation to end-of-study (up to 30 days)
Area under the plasma concentration-time curve from time zero to the last quantifiable rime point after administration (AUC0-t)
Area under the plasma concentration-time curve from time zero to the last quantifiable rime point after administration (AUC0-t)
Time frame: From randomisation to end-of-study (up to 30 days)
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)
Time frame: From randomisation to end-of-study (up to 30 days)
Elimination half-life (t1/2)
Elimination half-life (t1/2)
Time frame: From randomisation to end-of-study (up to 30 days)
Elimination rate constant (λz)
Elimination rate constant (λz)
Time frame: From randomisation to end-of-study (up to 30 days)
Clearance (CL)
Clearance (CL)
Time frame: From randomisation to end-of-study (up to 30 days)
Volume of distribution (Vz)
Volume of distribution (Vz)
Time frame: From randomisation to end-of-study (up to 30 days)
Myocardial infarction area percentage[Efficacy endpoints]
Ratio of infarct area to left ventricular area
Time frame: From randomisation to end-of-study (up to 30 days)
Absolute myocardial infarction area
Absolute myocardial infarction area
Time frame: From randomisation to end-of-study (up to 30 days)
Microvascular occlusion area
Microvascular occlusion area
Time frame: From randomisation to end-of-study (up to 30 days)
Left ventricular ejection fraction (LVEF)[Efficacy endpoints]
Left ventricular ejection fraction (LVEF)
Time frame: From randomisation to end-of-study (up to 30 days)
Left ventricular end-systolic volume (LVESV)[Efficacy endpoints]
Left ventricular end-systolic volume (LVESV)
Time frame: From randomisation to end-of-study (up to 30 days)
Left ventricular end-diastolic volume (LVEDV)[Efficacy endpoints]
Left ventricular end-diastolic volume (LVEDV)
Time frame: From randomisation to end-of-study (up to 30 days)
Creatine kinase isoenzyme MB mass (CK-MBmass)[Efficacy endpoints]
Creatine kinase isoenzyme MB mass (CK-MBmass)
Time frame: From randomisation to end-of-study (up to 30 days)
High-sensitivity troponin I (hsTnI)[Efficacy endpoints]
High-sensitivity troponin I (hsTnI)
Time frame: From randomisation to end-of-study (up to 30 days)
Survival[Efficacy endpoints]
Survival
Time frame: From randomisation to end-of-study (up to 30 days)
Qualitative detection of anti-drug antibodies in serum(Anti-drug antibody (ADA))
Qualitative detection of anti-drug antibodies in serum by ELISA, followed by calculation of the positivity rate as the number of positive samples divided by the total number of samples
Time frame: From randomisation to end-of-study (up to 30 days)
Plan to share: No — The individual participant data (IPD) will be shared when necessary
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Jul 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SGC001
Anterior Wall Myocardial Infarction →
Beijing Sungen Biomedical Technology Co., Ltd